Evaluation of efficacy and safety of a novel lipogel containing diclofenac: A randomized, placebo controlled, double-blind clinical trial in patients with signs and symptoms of osteoarthritis

• Main Authors: Amit Bhatia, PhD, M.Pharm., Vijay Goni, PhD, M.S. (Orthopaedic Surgery), M.B.B.S., Shruti Chopra, PhD, M.Pharm., Bhupinder Singh, PhD, M.Pharm., Om Prakash Katare, PhD, M.Pharm.
• Format: Article
• Language: English
• Published: Elsevier 2020-12-01
• Series: Contemporary Clinical Trials Communications
• Subjects: Nanomedicine; Liposome; Topical drug delivery; Efficacy; Osteoarthritis; Patient compliance
• Online Access: http://www.sciencedirect.com/science/article/pii/S2451865420301484

Background: Effectiveness and safety of pharmaceuticals is the prime concern of every osteoarthritis (OA) treatment. Chronic administration of NSAIDs, especially in case of geriatrics, through oral route tend to compromise the patient's safety, whereas topical treatments are not found to be effective owing their poor ability to deliver drug molecules.Thus, the present study deals with a randomized, double-blind, controlled trial conducted on patients with knee osteoarthritis (OA) for comparing the performance of a novel topical gel (liposomal gel) of diclofenac with a placebo and a marketed gel. Methods: The patients were treated and evaluated for 6 weeks as per the Western Ontario McMaster Universities (WOMAC) Index for OA. Patients were also observed for any adverse events. All the results were analyzed statistically using Kruskal-Wallis test, followed by Student's t-test at p ≤ 0.05. Results: Patients treated with liposomal gel showed statistically significantly improvements in treatment in comparison to the other tested formulations. All the treatments were found to be well tolerated with no report of adverse event. The results unequivocally demonstrated the superiority of the diclofenac liposomal gel, in the relieving the symptoms of OA of the knee, in comparison to placebo and marketed gel. Conclusion: From above results it was revealed that the drug in liposome have higher therapeutic potential. Thus, this can be a safe and effective option for the management of chronic OA especially for geriatric patients.